Werewolf Therapeutics Receives Nasdaq Deficiency Notice

Werewolf Therapeutics ( (HOWL) ) just unveiled an update.

On May 13, 2025, Werewolf Therapeutics received a deficiency letter from Nasdaq indicating that its stock price had fallen below the minimum bid requirement of $1.00 for 30 consecutive business days. This notice does not immediately affect the company’s listing, but Werewolf has 180 days to regain compliance by raising its stock price above $1.00 for at least 10 consecutive days. If unsuccessful, the company may seek an additional compliance period by transferring its listing to the Nasdaq Capital Market, though this involves meeting other criteria and paying a fee. Werewolf is actively monitoring its stock price and exploring options to address the deficiency, but there is no guarantee of success.

The most recent analyst rating on (HOWL) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Werewolf Therapeutics stock, see the HOWL Stock Forecast page.

Spark’s Take on HOWL Stock

According to Spark, TipRanks’ AI Analyst, HOWL is a Underperform.

Werewolf Therapeutics is navigating significant financial challenges, including ongoing losses and negative cash flows, heavily impacting its stock score. The bearish technical indicators and stressed valuation metrics further reflect the financial difficulties. Although there is some positive sentiment from corporate events regarding clinical progress, the overall stock score remains low, indicating substantial risks associated with the company’s current financial and market position.

To see Spark’s full report on HOWL stock, click here.

More about Werewolf Therapeutics

Werewolf Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative cancer therapies. The company is engaged in creating conditionally activated biologics for the treatment of cancer.

Average Trading Volume: 267,872

Technical Sentiment Signal: Sell

Current Market Cap: $45.77M

For an in-depth examination of HOWL stock, go to TipRanks’ Stock Analysis page.